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ABSTRACT
Background and Aims There are concerns that national population-based estimates of illicit drug use are
underestimated. We investigated this by comparing estimates of illicit substance use at age 24 from the Crime Survey
for England and Wales (CSEW) with a birth cohort (Avon Longitudinal Study of Parents and Children, ALSPAC) and by
comparing the Smoking and Alcohol Toolkit Studies (STS/ATS) to ALSPAC. Design Cross-sectional household survey
and cross-sectional data from onewave of a longitudinal birth cohort. Setting England andWales. Participants Young
adults aged 23–25 reporting on substance use in 2017 to CSEW (n = 1165), ALSPAC (n = 3389) and STS/ATS (n = 950).
Measurements Lifetime and past-year illicit drug use, smoking status and hazardous drinking at age 24. Findings The
2017 CSEW estimate of lifetime illicit drug use was 40.6%, compared with 62.8% in ALSPAC (risk difference %
[RD%] = 22.2%; 95% CI = 18.9–25.5%; P ≤ 0.001). The RD in lifetime use between ALSPAC and the CSEW was
23.2% (95% CI = 20.0–26.4%) for cannabis, 16.9% (95% CI = 14.4–19.4%) for powder cocaine and 24.8% (95% CI
= 22.6–27.0%) for amphetamine. Past-year drug use was 16.4% in CSEW, compared with 36.7% in ALSPAC
(RD% = 20.3%; 95% CI = 17.6–23.0%; P ≤ 0.001). For past-year substance use, the RD between ALSPAC and the CSEW
was 15.4% (95% CI = 12.9–17.9%) for cannabis, 14.8% (95% CI = 13.0%–16.6%) for powder cocaine and 15.9% (95%
CI = 14.5–17.4%) for amphetamine. Levels of current smoking were similar between STS (27.4%) and ALSPAC (29.4%).
Hazardous drinking was substantially higher in ALSPAC (60.3%) than the ATS (32.1%; RD% = 28.2%; 95% CI = 24.8–
31.6%; P ≤ 0.001). Conclusions The Avon Longitudinal Study of Parents and Children provides one source of validation
for measurements of drug use in government household surveys and indicates that illicit drug use may be underestimated
in the Crime Survey for England and Wales.
Keywords ALSPAC, ATS, crime survey for England and wales, illicit drug use, population-based household surveys,
STS, young adults.
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INTRODUCTION
Globally, substance misuse contributes to 27.8 million
disability adjusted life years (DALYs) [1]. Exposure to illicit
drugs during adolescence is associated with increased risk
of lifetime drug dependence, mental health problems, in-
jury, poorer educational performance [2,3] and negative
socioeconomic outcomes [3–5].
Reliablemeasures of illicit drug use are vital for develop-
ing effective policy and treatment programmes [6]. It can
be practically and methodologically challenging to accu-
rately determine the patterns and trends of illicit drug use
through population-based household surveys [7], and
illegality may discourage accurate reporting [8,9].
Different methodologies may provide insight into the
accuracy of population-based survey estimates of drug
use. The Avon Longitudinal Study of Parents and Children
(ALSPAC), a large United Kingdom (UK) birth cohort, has a
long-standing relationship between participants and
researchers. Participants report a high level of trust in the
study [10], whichmay facilitate accurate reporting of illicit
drug use. We compare illicit drug use data from the
ALSPAC birth cohort with the population-based household
Crime Survey for England and Wales (CSEW). We
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compared tobacco and alcohol use in ALSPAC with
national Smoking and Alcohol Toolkit Studies (STS/ATS)
as a negative control [11] to distinguishwhether any differ-
ences observed between CSEW and ALSPAC were because
of differences in the confounding structure of these popula-
tions that generally affected the level of reported use of both
legal and illicit substances, or whether differences may be
attributable to participant report bias resulting from the
illicit nature of the drug use [12].We expect the prevalence




The ALSPAC is a UK population-based birth cohort.
Pregnant women residing in the former Avon Health Au-
thority in South-West England, who had an expected deliv-
ery date between 1 April 1991 and 31 December 1992,
were invited to participate. Of their offspring, 13 988 chil-
dren were alive at age 1. Detailed methods are reported
elsewhere [13,14], with a fully searchable data dictionary
available on the ALSPAC study website. Ethical approval
for the study was obtained from the ALSPAC Ethics and
Law Committee and the local research ethics committees.
Study data were collected and managed using REDCap
electronic data capture tools hosted at the University of
Bristol [15,16] following participants privately completing
electronic computer-assisted questionnaires.
The CSEW is a household, population-based survey
[17] conducted face-to-face in a representative sample of
~35 000 households in England and Wales [18]. Elec-
tronic computer-assisted questionnaires are used for ques-
tions concerning illicit drug use [18]. The 70% response
rate for the CSEW is relatively high compared to other
household surveys [19].
The STS and the ATS are national household surveys
conducted by Ipsos MORI to monitor tobacco and alcohol
use behaviours of adults in England. These involvemonthly
face-to-face surveys [20]. Every month, ~1700 adults over
the age of 16 complete a computer-assisted survey [21].
The sampling is a hybrid between random probability and
simple quota and appears to result in a sample representa-
tive of the population on smoking prevalence and con-
sumption and sociodemographic characteristics [22,23].
However, because of this response, rate cannot be calcu-
lated due to lack of a definitive gross sample [24].
Study population
Figure 1 shows the flow of ALSPAC participants from
potential participants to the risk set for this analysis. Partic-
ipants were those reporting their lifetime and past-year
illicit drug use at a mean age of 24.0 years (SD = 0.8; inter-
quartile range = 23–25 years).
To accurately compare populations, a restricted sample
of participants, aged 23–25 years, were derived for the
CSEW and STS/ATS. From a sample of 1165, CSEW
2017 participants (mean age = 24, SD = 0.8) with com-
plete data for lifetime and past-year drug use was available
for 1146 and 1129 participants, respectively. STS/ATS
sample was 950 (mean age = 24; SD = 0.8).
Measures
Illicit drug use
ALSPAC participants reported their lifetime and past-year
use of cannabis and other illicit drugs (supporting
information Data S1 Appendices 1 and 2). To compare to
the CSEW data, we only classified ALSPAC participants as
reporting lifetime/past-year illicit drug use if they had
reported any use of cannabis, cocaine, crack, amphet-
amine, hallucinogens and opioids. Any participants who
responded ‘no use’ to all of these drugs, or who had re-
ported no use for 9 of 10 of the full complement of ALSPAC
drug items (supporting information Data S1 Appendix 1)
but had missing data for one remaining item, were coded
‘no use’.
In the CSEW, participants reported on lifetime and
past-year use of cannabis and 11 other drugs (supporting
information Data S1 Appendices 1 and 2). Participants
were coded as reporting lifetime/past-year illicit drug use
if they had reported any of these drugs within the respec-
tive time period.
Alcohol consumption
In both ALSPAC and the ATS, participants reported on al-
cohol use by completing the Alcohol Use Disorders Identifi-
cation Test for Consumption (AUDIT-C). AUDIT-C score>4
was the cut off for hazardous alcohol consumption [25].
Smoking status
In both ALSPAC and the STS, participants reported current
tobacco use. ALSPAC participants reporting smoking in the
past 30 days were classified as current smokers. In the STS,
participants were defined as current smokers if they
reported any cigarette smoking at the time of questioning.
Sociodemographic variables
Not in education, employment or training (NEET) was re-
ported in ALSPAC and CSEW. Socioeconomic status (SES)
was assessed using parent occupation in ALSPAC, coded
to a binary variable of high/medium (professional, mana-
gerial or skilled occupations) or low (semi-skilled or
manual occupations). In STS/ATS, low SES was defined
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as chief income earner on state pensions/casual or lowest
grade workers/unemployed/claiming state benefits.
Statistical analysis
All analyses were conducted using STATA version 15.1.
Differences between ALSPAC and the household surveys
(CSEW, STS and ATS) were tested using two-sample test
of proportions.
Sample Weighting
Inverse probability weighting (IPW) was applied to the
ALSPAC sample. Details are provided in supporting
information Data S1 Appendix 3. The inverse of the pre-
dicted probabilities were subsequently used as regression
weights to adjust the analysis sample to be representative
of the 9295 participants invited to the data collection
session.
The CSEW data had household weights and individual
weights applied to ensure representativeness to the 2011
census population and to account for missing data by
adjusting for differential non-response [18,26]. In this re-
stricted sample (aged 23–25), 2–3% of participants were
missing data on drug use.
STS/ATS datawere weighted to match the English pop-
ulation on age, social grade, region, tenure, ethnicity and
working status within sex. Data on smoking were com-
plete, and three participants were missing for alcohol use.
These analyses were not pre-registered, therefore the
results should be considered exploratory.
RESULTS
Table 1 shows there were slight differences in gender distri-
bution and social position. There were comparable num-
bers of women in the ALSPAC sample compared to the
CSEW, yet more than the STS/ATS; and lower proportion
of ALSPAC participants in lower social class or NEET than
the STS/ATS or the CSEW, respectively.
Figure 1 Risk set flow diagrams for each data set. ALSPAC = Avon Longitudinal Study of Parents and Children; CSEW=Crime Survey for England
and Wales; STS/ATS = Smoking and Alcohol Toolkit Studies. [Colour figure can be viewed at wileyonlinelibrary.com]
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Table 2 shows the prevalence comparison of past-year
and lifetime use of different illicit drugs. Past-year illicit
drug use was reported by 36.7% of the ALSPAC sample at
age 24, compared to 16.4% in the CSEW, a difference of
20.3% (95% CI = 17.6–23.0%, P ≤ 0.001); and in the
ALSPAC sample, 62.8% of the ALSPAC sample reported
any lifetime illicit drug use at age 24, compared to 40.6%
in the CSEW, a difference of 22.2% (95% CI = 19.0–
25.5%, P ≤ 0.001). The difference in lifetime illicit drug
use between ALSPAC and the CSEW was greatest for am-
phetamine, cannabis and powder cocaine, where the differ-
ence in prevalence was 24.8% (95% CI = 22.6–27.0%,
P ≤ 0.001), 23.2% (95% CI = 20.0–26.4%, P ≤ 0.001)
and 16.9% (95% CI = 14.4–19.4%, P ≤ 0.001) respec-
tively. The difference in past-year use between ALSPAC
and the CSEW was greatest for cannabis, powder cocaine
and amphetamine, where the difference in prevalence
was 15.4% (95% CI = 12.9–17.9%, P ≤ 0.001), 14.8%
(95% CI = 13.0–16.6%, P ≤ 0.001) and 15.9% (95% CI
= 14.5–17.3%, P ≤ 0.001), respectively.
It must be noted that the amphetamine category in
ALSPAC included 3,4-methylenedioxymethamphetamine
(MDMA), whereas CSEW listed ecstasy as a separate item.
This may contribute to some of the difference in the results
comparing amphetamine use. However, the proportion of
participants in CSEW endorsing ecstasy use (11.1% and
3.6% for lifetime and past-year use, respectively) indicates
this discrepancy in categorisationwould not completely ac-
count for the differences observed.
In ALSPAC, 60.3% of participants reported hazardous
drinking at age 24, compared to 32.1% in the ATS, a differ-
ence of 28.2% (95% CI = 24.8–31.6%, P ≤ 0.001). There
was no difference in tobacco use between ALSPAC and
STS (29.4% and 27.4%, respectively) (Table 3).
DISCUSSION
By comparing the CSEW household survey to data from a
birth cohort, we have found the CSEW may significantly
underestimate drug use in the general population. The ab-
solute difference between past-year and lifetime illicit drug
use in these two different sampleswere>20%, correspond-
ing to a greater than twofold difference. In our negative
control, there was no difference between ALSPAC and the
STS/ATS in tobacco use, but differences were observed in
hazardous drinking.
Different researchmethodologies can affect estimates of
illicit drug use [27]. It has been previously reported the
CSEW underestimates the prevalence of drug use in En-
gland and Wales [28]. Weisner and colleagues reported a
disparity of 31% between the recent drug use reported in
a household sample compared to other survey methods
[29]. Although the use of computerised surveys in the
CSEW provides increased anonymity, the inclusion of these
questions in the context of experience of crime may reduce
the likelihood of accurate illicit substance use disclosure
[30]. ALSPAC is a longitudinal study where participant
rapport and trust have been built up over time. ALSPAC’s
strict procedures of anonymity and confidentiality are
made explicitly clear to participants [31]. Qualitative re-
search reported participants were trusting and had faith
in ALSPAC and ‘considered themselves part of the ALSPAC
team’ [10]. This may help to promote more accurate and
honest drug use self-reporting.
The differences in hazardous alcohol use between
ALSPAC and the ATS (included as a negative control) were
large, but it has been suggested ATS may underestimate
hazardous alcohol consumption [32,33]. Although Local
Alcohol Profiles [34] suggest Bristol is slightly higher than
the England average for alcohol related harm, there is not
an exceptional regional difference. The 2014 Adult
Psychiatric Morbidity Survey (APMS) reported 19.7% of
participants had an AUDIT score>7, compared to 13% re-
ported using the ATS—a risk difference of 7%, or 50%, as
opposed to the 28% or >80%, we find in hazardous use
between the ATS and ALSPAC [32,33]. The ATS may un-
derestimate alcohol consumption compared with ALSPAC
and APMS if respondents feel less comfortable disclosing
Table 1 Sociodemographic characteristics for ALSPAC, CSEWand STS/ATS samples
Sociodemographic
ALSPAC n = 3389 %
(95% CI)
CSEW




and Alcohol Toolkit Study n = 950 %
RD% (95% CI)
P value















4.2 (3.4–5.3) – – 8.7 (7.0–10.7) 4.5 (6.4–2.6)
P ≤ 0.001
ALSPAC =Avon Longitudinal Study of Parents and Children; CSEW= Crime Survey for England andWales; RD%= risk difference % (ALSPAC as comparator);
STS/ATS = Smoking and Alcohol Toolkit Studies.
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their alcohol use with the market research company, Ipsos
MORI.
Strengths and limitations
All of the data collection methodologies have incomplete
response rates and rely on self-report. There is no evidence
drug and alcohol use is markedly different in Bristol and
Avon than elsewhere in England [35,36], but common
mental health disorders may be more prevalent in the
South West of England [36]. The differences in reported
use are greater than random error. ALSPAC response rates
for young adults are lower than earlier data collection
points [14] and therefore there is substantial missing data
from the Focus@24 + clinic (see Fig. 1). The original
ALSPAC sample was representative of Avon but not the
United Kingdom, and sociodemographic factors such as af-
fluence, sex and ethnicity impact on response rates and
therefore Caucasian people and those from more affluent
backgrounds are over-represented compared to the general
population [14]. However, IPW was used to make the
ALSPAC sample (n=3389) representative of the 9295 peo-
ple invited to the clinic, indicating selection bias is unlikely
to underlie present results.
Implications
It is important to ensure the CSEW and other govern-
ment household surveys accurately measure drug use.
The level of accuracy has implications for the ability of
drug policies, prevention and treatment interventions to
adequately meet the need of the population and accurate
estimates are required to improve the evidence-base in
the field. ALSPAC provides one source of validation and
indicates illicit drug use may be underestimated in the
CSEW. However, as ALSPAC participants are drawn from
one region of the United Kingdom, we urgently need to
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